As of 2026-01-10, the Intrinsic Value of Anavex Life Sciences Corp (AVXL) is -2.60 USD. This Anavex valuation is based on the model Peter Lynch Fair Value. With the current market price of 4.27 USD, the upside of Anavex Life Sciences Corp is -160.78%.
Based on its market price of 4.27 USD and our intrinsic valuation, Anavex Life Sciences Corp (AVXL) is overvalued by 160.78%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -2.60 - -2.60 | -2.60 | -160.78% |
| P/E | (3.84) - (9.55) | (6.72) | -257.4% |
| DDM - Stable | (3.53) - (12.14) | (7.83) | -283.5% |
| DDM - Multi | (1.05) - (2.96) | (1.57) | -136.8% |
| Market Cap (mil) | 381.52 |
| Beta | 1.15 |
| Outstanding shares (mil) | 89.35 |
| Enterprise Value (mil) | 278.95 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.07% |
| Cost of Debt | 5.00% |
| WACC | 8.03% |